Dan Shipley
Plus aucun poste en cours
Profil
The founder of CRS Management, Inc. is Dan Shipley.
He held the title of Director from 2010 to 2012.
Anciens postes connus de Dan Shipley
| Sociétés | Poste | Fin |
|---|---|---|
CRS Management, Inc.
 CRS Management, Inc. Miscellaneous Commercial ServicesCommercial Services Cetero Research is an industry leading contract research organization (CRO) in early phase research services. With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero’s proven track record allows the company to provide flexible and high quality drug development services, and its time-tested systems produce consistent and reliable data Cetero’s clients can trust. Cetero’s clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. In addition, Cetero owns and operates a full-scale central laboratory supporting Phase I-IV clinical trials in North and South America. | Fondateur | 26/06/2012 |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
CRS Management, Inc.
CRS Management, Inc. Miscellaneous Commercial ServicesCommercial Services Cetero Research is an industry leading contract research organization (CRO) in early phase research services. With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero’s proven track record allows the company to provide flexible and high quality drug development services, and its time-tested systems produce consistent and reliable data Cetero’s clients can trust. Cetero’s clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. In addition, Cetero owns and operates a full-scale central laboratory supporting Phase I-IV clinical trials in North and South America. | Commercial Services |
